Hi,
In the event that the efficacy seen thus far in MITCI is continued, Viralytics will be in a strong negotiating position for an approval study. While it is most unlikely and unwise for VLA to go alone, BMS may be compelled to partner with VLA particularly as revenues from Yervoy are in decline and also because there is nothing else in the target therapy area.
Just a snippet.
Aloha.
